Blindness News and Research

RSS

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.

18 Jul 2014

Encapsula releases 2 new liposome based products

Encapsula NanoSciences announces the release of two new liposome based products; Curcusome® and Taurosome™. Curcusome® or liposomal curcumin is a nutraceutical supplement that comes innovatively packaged in a powder release cap for consumer ease.

17 Jul 2014

Acute glaucoma is largely an inflammatory disease, say researchers

Researchers at the University of California, San Diego School of Medicine and Sun Yat-sen University in China have shown that acute glaucoma in mice is largely an inflammatory disease and that high pressure in the eye causes vision loss by setting in motion an inflammatory response similar to that evoked by bacterial infections.

14 Jul 2014

Improving type 2 diabetes management: an interview with Sir Michael Hirst, President of the International Diabetes Federation

One study suggested that 42 percent of people with type 2 diabetes who are treated for the disease do not reach their blood sugar goals, putting them at higher risk of organ and tissue damage, blindness and even death. We wanted to explore potential causes of clinical inertia among physicians and people with diabetes, which may lead to sub-optimal care.

14 Jul 2014

BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative research on Alzheimer's disease and the vision diseases of glaucoma and macular degeneration, today announced the recipients of new research grant awards, offered to 55 scientists in 19 U.S. states, the District of Columbia, and five foreign countries.

11 Jul 2014

New chemical compound protects against blindness and diabetes in animals

In a new study led by UC San Francisco scientists, a chemical compound designed to precisely target part of a crucial cellular quality-control network provided significant protection, in rats and mice, against degenerative forms of blindness and diabetes.

11 Jul 2014

New approach for developing personalized gene therapies to treat retinitis pigmentosa

Columbia University Medical Center researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss.

11 Jul 2014

LA BioMed researchers launch new project to improve diabetes management

Managing diabetes is a year-round challenge for anyone living with the disease. The challenge is even greater for underserved and uninsured people who often don't have easy access to the care they need to manage their diabetes.

10 Jul 2014

Quantel Medical receives FDA clearance for Optimis Fusion integrated laser platform

Quantel Medical today announced FDA 510(k) clearance for its Optimis Fusion integrated laser platform. The Optimis Fusion system combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to offer ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform.

10 Jul 2014

Dental pulp stem cells can protect retinal ganglion cells from death following injury

Researchers at the University of Birmingham, UK, led by Dr. Ben Scheven, Dr. Wendy Leadbeater and Ben Mead have discovered that stem cells isolated from the teeth, termed dental pulp stem cells (DPSC), can protect retinal ganglion cells (RGCs) from death following injury and promote regeneration of their axons along the optic nerve.

7 Jul 2014

Researchers discover a way to restore corneal surface

A Boston-based scientific collaborative, led by Harvard Stem Cell Institute researchers, has discovered a way to collect the best cell type for regenerating a damaged cornea-the clear membrane that covers the pupil and directs light into the back of the eye.

3 Jul 2014

Study results may help prevent eye injuries among soldiers

Researchers at The University of Texas at San Antonio are discovering that the current protective eyewear used by our U.S. armed forces might not be adequate to protect soldiers exposed to explosive blasts.

2 Jul 2014

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma.

1 Jul 2014

Light-sensitive molecule enables noninvasive silencing of neurons

Optogenetics, a technology that allows scientists to control brain activity by shining light on neurons, relies on light-sensitive proteins that can suppress or stimulate electrical signals within cells. This technique requires a light source to be implanted in the brain, where it can reach the cells to be controlled.

30 Jun 2014

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

The American Academy of Ophthalmology – the world's largest association of eye physicians and surgeons – is reminding the public that it does not recommend marijuana or other cannabis products for the treatment of glaucoma.

28 Jun 2014

Developmental psychologist explains the complexities of human mind

Developmental psychologist Daphne Maurer has spent more than four decades studying the complexities of the human mind.

28 Jun 2014

Study validates telemedicine approach to ROP screening

Trained non-physician evaluators who studied retinal images transmitted to computer screens at a remote central reading center successfully identified newborn infants likely to require a specialized medical evaluation for retinopathy of prematurity (ROP), a leading cause of treatable blindness.

28 Jun 2014

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal.

28 Jun 2014

University of Utah researcher to receive Nelson Trust Award for Retinitis Pigmentosa

Research to Prevent Blindness, a New York-based foundation, has announced that University of Utah researcher Wolfgang Baehr, Ph.D., will receive the Nelson Trust Award for Retinitis Pigmentosa-and an accompanying $100,000 to pursue new scientific leads to understand contributors to blindness.

27 Jun 2014

Telemedicine is effective strategy to screen for potentially blinding disease in infants

Telemedicine is an effective strategy to screen for the potentially blinding disease known as retinopathy of prematurity (ROP), according to a study funded by the National Eye Institute (NEI).

27 Jun 2014

Blindness News and Research

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Encapsula releases 2 new liposome based products

Acute glaucoma is largely an inflammatory disease, say researchers

Improving type 2 diabetes management: an interview with Sir Michael Hirst, President of the International Diabetes Federation

BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

New chemical compound protects against blindness and diabetes in animals

New approach for developing personalized gene therapies to treat retinitis pigmentosa

LA BioMed researchers launch new project to improve diabetes management

Quantel Medical receives FDA clearance for Optimis Fusion integrated laser platform

Dental pulp stem cells can protect retinal ganglion cells from death following injury

Researchers discover a way to restore corneal surface

Study results may help prevent eye injuries among soldiers

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

Light-sensitive molecule enables noninvasive silencing of neurons

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

Developmental psychologist explains the complexities of human mind

Study validates telemedicine approach to ROP screening

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

University of Utah researcher to receive Nelson Trust Award for Retinitis Pigmentosa

Telemedicine is effective strategy to screen for potentially blinding disease in infants

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News